All In Biotech

Drug Trial Radar · NCT06307925

A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors

A Phase I Open-label, Multi-center, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

122

Planned (sponsor's estimate)

Start

Mar 27, 2024

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
HC Biopharma Inc.Industry
Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a multicenter, open, single-arm, non-randomized, dose-escalation and dose-expansion, phase I clinical study in patients with advanced recurrent or metastatic solid tumors.The goal of this study is to evaluate the safety and tolerability of HC010 monotherapy in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • HC010Drug

    HC010 Q2W/28d intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicityTime frame: 28 days
  2. Adverse eventsTime frame: 2 years
  3. serious adverse eventsTime frame: 2 years
  4. Maximum Tolerated DoseTime frame: 2 years
  5. Recommended Dose for Phase II Clinical StudiesTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.